NeurologyLive® Friday 5 — April 26, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: The Role of Music & Movement in Parkinson Disease Treatment

Kenneth Ngo, MD, medical director for the Brain Injury Program at Brooks Rehabilitation’s 3 inpatient hospitals, highlighted how cotreatment between music therapy and physical therapy can significantly improve the overall quality of life for patients with Parkinson disease.

2: Safety Considerations for Ravulizumab in NMOSD: Sean Pittock, MD

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the safety of ravulizumab-cwvz (Ultomiris; Alexion) and the ways to avoid risks of meningococcal infection at the 2024 American Academy of Neurology Annual Meeting. [WATCH TIME: 3 minutes]

3: Dyskinesia: Importance of Giving Patients More Good “On- Time" In Parkinson’s Disease

In a new MEDcast episode, Stuart Isaacson, MD, Rajesh Pahwa, MD, and Fiona Gupta MD, discussed the management of dyskinesia and providing good ON time in Parkinson disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

4: NeuroVoices: Scott Perry, MD, on the Intricacies and Value of Diagnosing Lennox-Gastaut Syndrome

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center provided commentary on the need to properly diagnose Lennox-Gastaut syndrome and the negative downstream impacts of misdiagnosis or underdiagnosing patients.

5: Immunological Phenotypes of Multiple Sclerosis and Patient Race

In this new Peer Exchange episode, Ahmed Obeidat, MD, PhD, Erin Longbrake, MD, PhD, Stephen Krieger, MD, and Riley Bove, MD, discussed differences in immunologic phenotypes across racial boundaries. They also discuss data showing that, despite these differences, response to high-efficacy agents appears to be consistent regardless of race.